Related Experiment Videos
Telomere maintenance in childhood primitive neuroectodermal brain tumors
Domenico Didiano1, Tarek Shalaby, Doris Lang
1Neuro-Oncology Program, Department of Oncology, University Children's Hospital Zürich, 8032 Zürich, Switzerland.
Neuro-Oncology
|February 11, 2004
Summary
Epigallocatechin gallate (EGCG) inhibits telomerase activity in most childhood primitive neuroectodermal tumors (PNETs). This finding suggests EGCG as a potential therapeutic strategy for PNETs by targeting telomerase.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Primitive neuroectodermal tumors (PNETs) are common malignant brain tumors in children.
- Telomerase activation stabilizes telomere length, crucial for cancer cell immortalization.
- Epigallocatechin gallate (EGCG), a green tea polyphenol, inhibits telomerase and exhibits anticancer properties.
Purpose of the Study:
- To investigate the role of human telomerase reverse transcriptase (hTERT) mRNA expression in PNETs.
- To assess telomerase activity and telomere length in PNET cell lines.
- To evaluate the effect of EGCG on telomerase activity and PNET cell proliferation.
Main Methods:
- Real-time reverse transcriptase-polymerase chain reaction (RT-PCR) for hTERT mRNA expression.
- Quantitative telomeric repeat amplification protocol (TRAP) for telomerase activity.
- Terminal restriction fragment (TRF) analysis for telomere length.
- In vitro treatment of PNET cell lines with EGCG.
Main Results:
- 76% of primary PNET samples showed significantly upregulated hTERT mRNA expression compared to normal brain tissue.
- A positive correlation was observed between hTERT mRNA expression and telomerase activity in PNET cell lines.
- EGCG dose-dependently inhibited telomerase activity and proliferation in telomerase-positive PNET cell lines.
Conclusions:
- Telomerase plays a significant role in the pathogenesis of most PNETs.
- Some PNETs may utilize alternative mechanisms for telomere length maintenance.
- EGCG demonstrates potential as a novel therapeutic agent for childhood PNETs by inhibiting telomerase.